The Competitive Market: Our 10 Cellestial Steps
These are the 10 steps that define Cellestial Health’s place in the market. We’ve outlined these steps to provide a clear roadmap for how we differentiate ourselves, from pioneering science to strategic positioning. Each step reflects our commitment to advancing Parkinson’s treatment and solidifying our leadership in this evolving landscape.
Pioneering a New Frontier in Parkinson’s Treatment
Cellestial Health is pioneering a new frontier in Parkinson’s treatment by targeting astrocytic networks, a novel approach that sets us apart in a highly competitive and evolving market. As Parkinson’s continues to be the fastest-rising cause of disability and death among neurodegenerative disorders, with no disease-modifying treatments currently available, the need for new, impactful solutions is more urgent than ever.
Market Growth and Global Opportunity
The global Parkinson’s drug market is projected to exceed $8 billion by 2026, with North America maintaining the largest market share and Asia-Pacific experiencing the fastest growth.
Strategically Positioned for Impact
At Cellestial Health, we are strategically positioned to capture this opportunity by addressing the root causes of Parkinson’s, rather than simply masking symptoms.
A Revolutionary Approach to Parkinson’s
Around 90% of Parkinson’s patients have idiopathic Parkinson’s, meaning the disease develops without a clear cause such as trauma or genetic mutations. The existing treatments temporarily manage motor symptoms but often lead to severe side effects, such as hallucinations and involuntary movements. These therapies also inadequately address the non-motor symptoms that patients frequently experience including; depression, gastrointestinal issues, and sleep related issues. At Cellestial Health, our approach offers the potential to revolutionise this landscape.
Targeting Astrocytic Networks for Comprehensive Care
By focusing on astrocytic network biology, we aim to provide therapies that address both motor and non-motor symptoms, whilst minimising side effects.
Next-Generation Therapies for a Growing Market
Our innovative strategy targets the underlying mechanisms of Parkinson’s, offering real hope to patients and placing us at the forefront of next-generation therapies in this $8 billion total addressable market.
Targeting Astrocytes for Brain Integrity
While many competitors focus on replacing dopamine in the brain, Cellestial Health offers a truly differentiated solution by targeting astrocytes, the critical cells that play a key role in maintaining brain integrity – this includes protection of the dopaminergic system, but also extends beyond to other functions such as cognition, memory, and sleep.
Addressing Core Disruptions, Not Just Symptoms
Our approach stands apart by addressing the underlying disruptions in astrocytic networks that contribute to disease progression, rather than simply targeting and managing symptoms.
A Step Ahead By Targeting Disease Upstream
Other emerging investigational therapies in Parkinson’s focus on immunomodulatory approaches (such as inflammasome inhibition), calcium signalling modulators, and anti-synuclein treatments. What sets our strategy apart is that we target molecular disruptions upstream of these disease hallmarks.
Early Intervention with Lasting Impact
By normalising astrocytic function at the earliest stages, our solution has the potential to stop disease progression at the time of diagnosis. At later stages of Parkinson’s, this approach can be complementary to dopamine replacement, minimising the dose required and thus managing side effects.
